|
Rituximab (Rituxan)
Rituximab (Rituxan) is the first monoclonal antibody approved by the US Food and Drug Administration for the treatment of cancer. It is a genetically engineered chimeric (murine-human) monoclonal antibody (mAb) directed against the CD20 antigen found on the surface of normal and malignant B cells.
Possible Side-Effects
- During infusion - changes in breathing, fever, chills, dizziness, lightheadedness, nausea, vomiting, runny nose, pain
- B-cell depletion, causing increased susceptibility to infection
- Loss of appetite
- Dizziness
- Headache
- Itching, rash or hives
- Muscle aches
- Nausea
- Night sweats
- Chills
- Difficulty breathing
Bruce's Non-Hodgkin's Lymphoma Story
Background courtesy of :
Windy's Fashionable Page Designs
|